Gadopiclenol has been developed by both Bracco and Guerbet as a high-relaxivity macrocyclic gadolinium-based contrast agent (GBCA), with the goal of allowing radiology practices to use half the gadolinium dose of existing GBCAs and alleviate concerns over potentially toxic effects of gadolinium in some patients.
Both companies have rights to sell gadopiclenol under their own brand names, with Bracco marketing it as Vueway and Guerbet selling it as Elucirem.
The rest of the top five was rounded out by an update provided by Philips on its hybrid angiography/CT suite that uses spectral detectors, a new artificial intelligence platform from Nvidia, and a new ultrasound scanner from Samsung.
- Bracco prepares launch of its version of gadopiclenol MRI contrast
- Philips reports advances in hybrid angio/CT suite with spectral CT detector
- Guerbet gets FDA approval for Elucirem lower-dose MRI contrast
- Nvidia unveils AI platform, new MONAI release at GTC
- Samsung introduces V7 ultrasound system
- Konica Minolta gets FDA nod for digital x-ray system
- GE's MRI recon software nabs new FDA clearance
- BWXT Medical seeks FDA approval for Tc-99m generator
- Intelligent Ultrasound unveils new NeedleTrainer
- Stryker unveils Q Guidance spine surgery platform
Copyright © 2022 AuntMinnie.com